Health Care · Biological Products, (No Diagnostic Substances) · NYSE · CIK 1015820 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $41.81Day −1.11%Mkt cap $9.1B1Y −17.5%Off 52W high −27.7%Vol (1Y) 34.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$25.77 |
| Implied upside−38.4% |
| Valuation confidenceMEDIUM |
| Price impliesAGGRESSIVE · 17.4% growth |
| Short interest3.7% of sh out |
| Days to cover2.1d |
| 13F net flow (QoQ)+0.21% |
| Top-10 13F concentration47.7% |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$2.09B |
| Earnings (TTM)$424.9M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−6.3% |
| 1Y−17.5% |
| 3Y−9.7% |
| 5Y−19.0% |
| 10Y+57.7% |
| Since incept. (ann.)+6.0% |
Total return through 2026-07-29 · series begins 2005-07-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)34.1% |
| Ann. volatility (3Y)27.7% |
| Sharpe (1Y)−0.40 |
| Sharpe (3Y)0.00 |
| Max drawdown (1Y)−41.4% |
| Max drawdown (3Y)−41.4% |
| Beta (3Y vs SPY)0.50 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 14.4M | $575M | 6.62% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.4M | $338M | 3.89% | −0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $247M | 2.81% | new |
| DEUTSCHE BANK AG\ | 5.6M | $224M | 2.58% | new |
| BlackRock, Inc. | 5.3M | $210M | 2.42% | new |
| Amundi | 4.8M | $190M | 2.19% | new |
| MORGAN STANLEY | 4.2M | $168M | 1.93% | new |
| EARNEST PARTNERS LLC | 3.9M | $155M | 1.78% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
No reported quarters on file for QGEN.
